Molnupiravir EIDD-2801 is a highly potent oral bioavailable form of a ribonucleoside analogue that inhibiting replication of a variety of RNA viruses, including SARS-CoV-2.
Figure1 Molecular structure of NHC (β-D-N4-hydroxycytidine)
The structure is a ribonucleotide (the building block of RNA) analog that replaces normal ribonucleotide when the virus replicates, thus preventing the virus from replicating. The drug does not block the Ia enzyme, does not bind to any target, and does not block the enzyme's action.
At present, the preclinical study data of this drug indicate that this drug can inhibit SARS-CoV-2, MERS-CoV, SARS-CoV at the cellular level, and SARS-CoV-2 at the animal (mouse) level. The cell-level data are shown in Figure 2 below.
It is a non-inhibitor broad-spectrum anti-coronavirus drug .
Molnupiravir ;EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19.EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung.In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus.EIDD-2801 is a prodrug of EIDD-1931.
Certificate + Exhibition
Packing And Shipping
FAQ
Comments